. 2022 Dec 3;22:521. doi: 10.1186/s12872-022-02928-8

Table 4.

MPO levels as a function of heart failure, previous heart attack, and PCI in the study group

	MPO [ng/ml] Average mean (SD)
	Female Male	19.8 (8.0) 18.8 (8.0) P = 0.67	24.2 (6.3) 20.2 (9.9) P = 0.29	14.7 (6.9) 12.2 (4.8) P = 0.28
NYHA scale	0 ≥ 1	17.9 (6.6) 21.7 (10.4) P = 0.08	20.6 (7.1) 22.3 (12.5) P = 0.63	15.4 (5.0) 20.5 (5.4) P = 0.01
MI	No Yes	20.4 (10.0) 17.7 (4.9) P = 0.19	23.8 (10.4) 17.3 (5.3) P = 0.05	14.4 (5.8) 18.0 (4.7) P = 0.08
PCI	No Yes	19.2 (8.5) 19.0 (7.7) P = 0.88	22.5 (8.9) 20.5 (9.5) P = 0.56	15.3 (6.5) 12.3 (4.8) P = 0.36

MPO [ng/ml]
Average mean (SD)

All patients

nDM

Female

Male

19.8 (8.0)

18.8 (8.0)

P = 0.67

24.2 (6.3)

20.2 (9.9)

P = 0.29

14.7 (6.9)

12.2 (4.8)

P = 0.28

NYHA scale

≥ 1

17.9 (6.6)

21.7 (10.4)

P = 0.08

20.6 (7.1)

22.3 (12.5)

P = 0.63

15.4 (5.0)

20.5 (5.4)

P = 0.01

Yes

20.4 (10.0)

17.7 (4.9)

P = 0.19

23.8 (10.4)

17.3 (5.3)

P = 0.05

14.4 (5.8)

18.0 (4.7)

P = 0.08

PCI

Yes

19.2 (8.5)

19.0 (7.7)

P = 0.88

22.5 (8.9)

20.5 (9.5)

P = 0.56

15.3 (6.5)

12.3 (4.8)

P = 0.36

DM Participants with diabetes type 2, nDM Participants without diabetes type 2, MI Myocardial infarction, MPO Myeloperoxidase, NYHA New York Heart Association, PCI Percutaneous coronary interventions, SD Standard deviation